CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 0.841 USD -5.23%
Market Cap: 65.8m USD

CytomX Therapeutics Inc
Investor Relations

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).

Show more
Loading

Earnings Calls

2024 Q3
Nov 7, 2024
Show Transcript
Previous
Next
CytomX Advances Clinical Pipeline with Promising Updates
2024 Q3
Nov 7, 2024

CytomX Therapeutics is excited about its clinical pipeline, particularly its three key programs: CX-904, CX-2051, and CX-801, each poised for significant updates in 2025. The company reported third-quarter revenue of $33.4 million, up from $26.4 million, supported by collaborations with major partners. CX-2051 shows encouraging progress in Phase I, targeting an estimated 300,000 patients. CX-801 has begun its Phase I study, aiming for improved efficacy in melanoma, with data expected in the second half of 2025. With $118 million in cash, CytomX anticipates stability through end-2025 while focusing on strategic advancements across its pipeline.

Show Full Analysis

Management

Dr. Sean A. McCarthy DPHIL
Chairman & CEO
No Bio Available
Dr. Marcia P. Belvin Ph.D.
Senior VP & Chief Scientific Officer
No Bio Available
Mr. Jeffrey Landau B.S., M.B.A.
Senior VP, Head of Strategy & Chief Business Officer
No Bio Available
Mr. Christopher W. Ogden
Chief Financial Officer
No Bio Available
Mr. Lloyd A. Rowland Jr., J.D.
Senior VP, General Counsel, Chief Compliance Officer & Secretary
No Bio Available
Ms. Danielle Olander-Moghadassian
Senior VP & Chief Human Resources Officer
No Bio Available
Ms. Leslie Robbins
Senior Vice President of Intellectual Property
No Bio Available
Dr. Yu-Waye Chu M.D.
Chief Medical Officer
No Bio Available
Ms. Dawn Benson
Senior Vice President of Quality & Product Manufacturing
No Bio Available
Dr. Hoyoung Huh M.D., Ph.D.
Special Advisor to Chief Executive Officer
No Bio Available

Contacts

Address
CALIFORNIA
South San Francisco
151 Oyster Point Blvd, Suite 400
Contacts
+16505153185.0
cytomx.com